Loading
Adding pembrolizumab to trastuzumab and chemotherapy improved response and progression-free survival in HER2-positive advanced gastric cancer, with the benefit concentrated in tumours that also express PD-L1.
Phase 3 placebo-controlled trial of 698 patients with untreated HER2-positive advanced gastric or junctional adenocarcinoma randomised to pembrolizumab or placebo with trastuzumab and fluoropyrimidine-platinum chemotherapy.
Median progression-free survival was 10.0 versus 8.1 months (hazard ratio 0.72) overall and 10.8 versus 7.2 months in PD-L1 combined positive score 1 or more (hazard ratio 0.70); response was 73 versus 60 percent, and the final analysis showed an overall survival benefit in the PD-L1-positive population (20.0 versus 15.7 months).
Pembrolizumab with trastuzumab and chemotherapy is the first-line standard for HER2-positive gastric cancer with a PD-L1 combined positive score of 1 or more.
Shares KEYNOTE-811, Trastuzumab, Pembrolizumab.
Shares HER2-positive gastric cancer, Trastuzumab, Pembrolizumab.
Shares Trastuzumab, Pembrolizumab.
Shares HER2-positive gastric cancer, Trastuzumab, Pembrolizumab.
Shares HER2-positive gastric cancer, Trastuzumab.
Shares HER2-positive gastric cancer, Trastuzumab, Pembrolizumab.
Shares The Lancet, Pembrolizumab.
Shares Trastuzumab, Pembrolizumab.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/